Literature DB >> 19008400

Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus.

Nancy D Ulbrandt1, Hong Ji1, Nita K Patel1, Arnita S Barnes1, Susan Wilson1, Peter A Kiener1, JoAnn Suzich1, Michael P McCarthy1.   

Abstract

Human metapneumovirus (hMPV) is genetically related to respiratory syncytial virus (RSV); both cause respiratory tract illnesses ranging from a mild cough to bronchiolitis and pneumonia. The F protein-directed monoclonal antibody (mAb) palivizumab has been shown to prevent severe lower respiratory tract RSV infection in animals and humans. We have previously reported on a panel of mAbs against the hMPV F protein that neutralize hMPV in vitro and, in two cases, in vivo. Here we describe the generation of hMPV mAb-resistant mutants (MARMs) to these neutralizing antibodies. Sequencing the F proteins of the hMPV MARMs identified several neutralizing epitopes. Interestingly, some of the epitopes mapped on the hMPV F protein coincide with homologous regions mapped previously on the RSV F protein, including the site against which the broadly protective mAb palivizumab is directed. This suggests that these homologous regions play important, conserved functions in both viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008400      PMCID: PMC2885031          DOI: 10.1099/vir.0.2008/005199-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  31 in total

1.  Modelling the structure of the fusion protein from human respiratory syncytial virus.

Authors:  Brian J Smith; Michael C Lawrence; Peter M Colman
Journal:  Protein Eng       Date:  2002-05

2.  Production and characterization of neutralizing monoclonal antibodies against human metapneumovirus F protein.

Authors:  Xiaoming Ma; Rika Endo; Takashi Ebihara; Nobuhisa Ishiguro; Hiroaki Ishiko; Hideaki Kikuta
Journal:  Hybridoma (Larchmt)       Date:  2005-08

3.  Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains.

Authors:  Sander Herfst; Miranda de Graaf; Eefje J A Schrauwen; Nancy D Ulbrandt; Arnita S Barnes; Kannaki Senthil; Albert D M E Osterhaus; Ron A M Fouchier; Bernadette G van den Hoogen
Journal:  J Gen Virol       Date:  2007-10       Impact factor: 3.891

4.  Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay.

Authors:  Craig J Morton; Rachel Cameron; Lynne J Lawrence; Bo Lin; Melinda Lowe; Angela Luttick; Anthony Mason; Jenny McKimm-Breschkin; Michael W Parker; Jane Ryan; Michael Smout; Jayne Sullivan; Simon P Tucker; Paul R Young
Journal:  Virology       Date:  2003-07-05       Impact factor: 3.616

5.  Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; D Andreu; C Carreño; P Whyte; G Taylor; J A Melero
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

6.  Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.

Authors:  G R Lounsbach; C Bourgeois; W H West; J W Robinson; M J Carter; G L Toms
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

7.  Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design.

Authors:  Mia MacPhail; Jeanne H Schickli; Roderick S Tang; Jasmine Kaur; Christopher Robinson; Ron A M Fouchier; Albert D M E Osterhaus; Richard R Spaete; Aurelia A Haller
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

8.  A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.

Authors:  Roderick S Tang; Kutubuddin Mahmood; Mia Macphail; Jeanne M Guzzetta; Aurelia A Haller; Hui Liu; Jasmine Kaur; Heather A Lawlor; Elizabeth A Stillman; Jeanne H Schickli; Ron A M Fouchier; Albert D M E Osterhaus; Richard R Spaete
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

9.  Characterization of human metapneumoviruses isolated from patients in North America.

Authors:  Teresa C T Peret; Guy Boivin; Yan Li; Michel Couillard; Charles Humphrey; Albert D M E Osterhaus; Dean D Erdman; Larry J Anderson
Journal:  J Infect Dis       Date:  2002-05-03       Impact factor: 5.226

10.  A newly discovered human pneumovirus isolated from young children with respiratory tract disease.

Authors:  B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

View more
  22 in total

1.  Human metapneumovirus fusion protein triggering: Increasing complexities by analysis of new HMPV fusion proteins.

Authors:  J Tyler Kinder; Edita M Klimyte; Andres Chang; John V Williams; Rebecca Ellis Dutch
Journal:  Virology       Date:  2019-03-07       Impact factor: 3.616

2.  A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.

Authors:  Yael Bar-Peled; Darren Diaz; Alma Pena-Briseno; Jackelyn Murray; Jiachen Huang; Ralph A Tripp; Jarrod J Mousa
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

3.  A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Authors:  Jennifer E Schuster; Reagan G Cox; Andrew K Hastings; Kelli L Boyd; Jay Wadia; Zhifeng Chen; Dennis R Burton; R Anthony Williamson; John V Williams
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

4.  A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.

Authors:  Charles J Russell; Bart G Jones; Robert E Sealy; Sherri L Surman; John N Mason; Randall T Hayden; Ralph A Tripp; Toru Takimoto; Julia L Hurwitz
Journal:  Virology       Date:  2017-06-09       Impact factor: 3.616

5.  Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells.

Authors:  Homero San-Juan-Vergara; Viviana Sampayo-Escobar; Niradiz Reyes; Byeong Cha; Lisandro Pacheco-Lugo; Terianne Wong; Mark E Peeples; Peter L Collins; Maria Eugenia Castaño; Shyam S Mohapatra
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

6.  Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.

Authors:  Andrew K Hastings; John J Erickson; Jennifer E Schuster; Kelli L Boyd; Sharon J Tollefson; Monika Johnson; Pavlo Gilchuk; Sebastian Joyce; John V Williams
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

7.  Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.

Authors:  Avik Banerjee; Jiachen Huang; Scott A Rush; Jackelyn Murray; Aaron D Gingerich; Fredejah Royer; Ching-Lin Hsieh; Ralph A Tripp; Jason S McLellan; Jarrod J Mousa
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-13       Impact factor: 12.779

8.  Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site.

Authors:  Xiaolin Wen; Jens C Krause; George P Leser; Reagan G Cox; Robert A Lamb; John V Williams; James E Crowe; Theodore S Jardetzky
Journal:  Nat Struct Mol Biol       Date:  2012-03-04       Impact factor: 15.369

Review 9.  Human metapneumovirus in adults.

Authors:  Lenneke E M Haas; Steven F T Thijsen; Leontine van Elden; Karen A Heemstra
Journal:  Viruses       Date:  2013-01-08       Impact factor: 5.048

10.  Phylogenetic and phylodynamic analyses of human metapneumovirus in Buenos Aires (Argentina) for a three-year period (2009-2011).

Authors:  Ana Julia Velez Rueda; Alicia Susana Mistchenko; Mariana Viegas
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.